KPI data tables
Aflac operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Japan NAP (¥ billions) |
|---|---|
| Q3 2026 | 18.8 |
| Q2 2026 | 19.6 |
| Q1 2026 | 17.7 |
| Q4 2025 | 19.9 |
| Q3 2025 | 19.6 |
| Q2 2025 | 20.7 |
| Q1 2025 | 14.1 |
| Q4 2024 | 17.2 |
| Q3 2024 | 17.5 |
| Q2 2024 | 16.8 |
| Q1 2024 | 12.5 |
| Q4 2023 | 15.8 |
| Q3 2023 | 15.6 |
| Q2 2023 | 16.1 |
| Q1 2023 | 13.2 |
| Q4 2022 | 16.2 |
| Q3 2022 | 13.9 |
| Q2 2022 | 12.7 |
| Q1 2022 | 11.9 |
| Q4 2021 | 14.6 |
| Q3 2021 | 12.6 |
Source: Aflac Incorporated Form 8-K earnings statistical supplement and Exhibit 99.1 earnings releases, Aflac Japan Sales Results, Total New Annualized Premium Sales in yen. Q1 2024 through Q2 2026 from the supplement for the period ended June 30, 2026 (https://www.sec.gov/Archives/edgar/data/4977/000162828026054333/afl063026-financialsupplem.htm); Q3 2026 (18,807 million yen) from the supplement for the period ended September 30, 2026, filed 2026-11-04 (https://www.sec.gov/Archives/edgar/data/4977/000162828026070181/afl093026-financialsupplem.htm), millions of yen converted to billions at one decimal. Q3 2021 through Q4 2023 from each quarter's Exhibit 99.1 current-quarter print in yen billions (Q3 2021: https://www.sec.gov/Archives/edgar/data/4977/000000497721000142/aflex991-q32021.htm; Q4 2023: https://www.sec.gov/Archives/edgar/data/4977/000000497724000006/aflex991-q42023.htm). Later filing wins. Overlapping Q1 2025 through Q2 2026 matched the prior IR-sourced points.
| Period | Cancer | Medical and other health | Life insurance | Other |
|---|---|---|---|---|
| 2025 | 3,405 | 2,131 | 1,227 | 129 |
| 2024 | 3,545 | 2,181 | 1,225 | 134 |
| 2023 | 4,063 | 2,631 | 1,532 | 149 |
Source: Aflac Incorporated Form 10-K for the year ended December 31, 2025, Note 8 Policy Liabilities, Summary of Net Earned Premiums Recognized by reporting segment and product type (in millions). https://www.sec.gov/Archives/edgar/data/4977/000162828026011402/afl-20251231.htm
| Period | Aflac Japan | Aflac US |
|---|---|---|
| 2025 | 6,744 | 5,999 |
| 2024 | 6,930 | 5,829 |
| 2023 | 8,047 | 5,675 |
Source: Aflac Incorporated Form 10-K for the year ended December 31, 2025, Item 8 segment operations table, net earned premiums for Aflac Japan and Aflac U.S. (in millions). https://www.sec.gov/Archives/edgar/data/4977/000162828026011402/afl-20251231.htm
| Period | US annualized premiums in force ($ billions) |
|---|---|
| 2025 | 6.7 |
| 2024 | 6.4 |
| 2023 | 6.2 |
Source: Aflac Incorporated Form 10-K, Aflac U.S. Segment MD&A, annualized premiums in force at December 31. 2025 10-K (6.7 versus 6.4, +4.9% in 2025 and +3.6% in 2024): https://www.sec.gov/Archives/edgar/data/4977/000162828026011402/afl-20251231.htm. 2024 10-K (6.4 versus 6.2): https://www.sec.gov/Archives/edgar/data/4977/000000497725000047/afl-20241231.htm.
| Period | US NAP ($ millions) |
|---|---|
| Q3 2026 | 403 |
| Q2 2026 | 349 |
| Q1 2026 | 318 |
| Q4 2025 | 551 |
| Q3 2025 | 390 |
| Q2 2025 | 340 |
| Q1 2025 | 309 |
| Q4 2024 | 534 |
| Q3 2024 | 379 |
| Q2 2024 | 331 |
| Q1 2024 | 298 |
| Q4 2023 | 559 |
| Q3 2023 | 359 |
| Q2 2023 | 324 |
| Q1 2023 | 315 |
| Q4 2022 | 545 |
| Q3 2022 | 334 |
| Q2 2022 | 305 |
| Q1 2022 | 299 |
| Q4 2021 | 464 |
| Q3 2021 | 299 |
Source: Aflac Incorporated Form 8-K earnings statistical supplement and Exhibit 99.1 earnings releases, Aflac U.S. Sales Results, New Annualized Premiums Sales, USD millions. Q1 2024 through Q2 2026 from the supplement for the period ended June 30, 2026 (https://www.sec.gov/Archives/edgar/data/4977/000162828026054333/afl063026-financialsupplem.htm). Q3 2026 ($403 million) from the supplement for the period ended September 30, 2026, filed 2026-11-04 (https://www.sec.gov/Archives/edgar/data/4977/000162828026070181/afl093026-financialsupplem.htm). Q3 2021 through Q4 2023 from each quarter's Exhibit 99.1 current-quarter print (Q3 2021: https://www.sec.gov/Archives/edgar/data/4977/000000497721000142/aflex991-q32021.htm; Q4 2023: https://www.sec.gov/Archives/edgar/data/4977/000000497724000006/aflex991-q42023.htm). Later filing wins. Overlapping Q1 2025 through Q2 2026 matched the prior IR-sourced points.